News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Daiichi Sankyo Co Ltd. Says U.S. FDA Rejects Anaemia Drug
March 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, March 12 (Reuters) - U.S. regulators have rejected Daiichi Sankyo Co Ltd's injectable anaemia drug Injectafer for the broad treatment of uterine bleeding and in a surprise move also knocked it back for a narrower use.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Asia
Food and Drug Administration (FDA)
Daiichi Sankyo
MORE ON THIS TOPIC
Regulatory
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
November 17, 2025
·
1 min read
·
Tristan Manalac
Government
Signs of Frustration Build Between Kennedy and FDA Commissioner Makary
November 17, 2025
·
2 min read
·
Tristan Manalac
China
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
November 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker